The protection of ATL-III on H9c2 cardiomyocytes may be related to the inhibition of ERS and downregulation of the GRP78/PERK/CHOP signaling pathway, which provided a new target for the management of HF. This evidence concerns the gene DDIT3 and hydrops fetalis.